journal
MENU ▼
Read by QxMD icon Read
search

Recent Patents on Anti-cancer Drug Discovery

journal
https://www.readbyqxmd.com/read/28875828/synergistic-effect-of-epidermal-growth-factor-receptor-inhibitors-and-ionization-radiation-in-cancer-treatment
#1
Zahra Shaghaghi, Seyed Jalal Hosseinimehr
cancer cells to treatment. OBJECTIVE: This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment. METHOD: The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers. RESULTS: The specific inhibition has been introduced as targeted therapy for treatment of cancers...
August 29, 2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28786345/bet-inhibitors-as-anticancer-agents-a-patent-review
#2
Imran Ali, Gildon Choi, Kwangho Lee
BACKGROUND: Bromodomain and extra terminal (BET) family of bromodomain proteins (BRDs), comprised of four members in humans (BRD2, BRD3, BRD4, and BRDT), has emerged as a promising new cancer target class for small-molecule drug discovery. OBJECTIVE: This review discusses the patent literature of BET inhibitors (2010-2017) for the treatment of cancer and other related diseases. METHOD: BET proteins act as 'epigenetic readers' and bind to acetylated lysine residues on the tails of histones H3 and H4...
August 8, 2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28748750/chemical-space-of-flt3-inhibitors-as-the-potential-anti-aml-drugs
#3
Qingyuan Lan, Yanle Zhi, Hao Heng, Xiaoxing Guo, Haichun Liu, Yadong Chen, Tao Lu, Shuai Lu
FLT3 is a member of receptor tyrosine kinase III family, expressed in normal bone marrow cells, early progenitor cells and hematopoietic stem cells. The aberrant expression and function of FLT3 are strongly related leukemia, especially acute myeloid leukemia. Its complex amino-acid residues mutations can induce ligand independent activation and downstream signaling transduction, leading to constant proliferation of hematological tumor cells with poor prognosis. Hence FLT3 serves as a promising target in AML chemotherapy...
July 27, 2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28482791/3d-qsar-comfa-comsia-and-molecular-docking-studies-on-histone-deacetylase-1-selective-inhibitors
#4
Tooba Abdizadeh, Razieh Ghodsi, Farzin Hadizadeh
BACKGROUND: Histone deacetylases (HDACs) are attractive therapeutic targets for the treatment of cancer and other diseases. There are numerous published patent applications till 2017. It was claimed that novel HDACIs were optimized as potential drug candidates, designed for regional or systemic release, and created as significant inhibitors. OBJECTIVE: In the present study, 3D-QSAR and molecular docking were used to provide a theoretical basis for finding highly potent anti-tumor drugs...
May 8, 2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28393711/emerging-drugs-for-the-treatment-of-cancer-pain-a-review-of-patent-literature-in-2014
#5
R N Brooke Anderson, Samuel Lee, Alaa Abd-Elsayed
BACKGROUND: Pain in oncology patients may be related to underlying disease process, as well as a side effect of chemotherapy and radiation. More than half of all patients with a diagnosis of cancer experience pain, which is often poorly controlled. As such, the treatment of pain in oncology patients demonstrates a significant need to develop new treatment options. OBJECTIVE: This review summarizes 35 patents on the treatment of pain among cancer patients. METHOD: A thorough literature review of all patents filed in 2014 was conducted using PubMed and http://ep...
April 6, 2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28637419/pharmacological-inhibitors-of-nad-biosynthesis-as-potential-an-ticancer-agents
#6
Stephanie Lucas, Claire Soave, Gazal Nabil, Zainab Sabry Othman Ahmed, Guohua Chen, Hossny Awad El-Banna, Q Ping Dou, Jian Wang
BACKGROUND: Alteration of cellular metabolism is a hallmark of cancer, which underlies exciting opportunities to develop effective, anti-cancer therapeutics through inhibition of cancer metabolism. Nicotinamide Adenine Dinucleotide (NAD+), an essential coenzyme of energy metabolism and a signaling molecule linking cellular energy status to a spectrum of molecular regulation, has been shown to be in high demand in a variety of cancer cells. Depletion of NAD+ by inhibition of its key biosynthetic enzymes has become an attractive strategy to target cancer...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28595538/immune-cells-act-as-promising-targets-for-the-treatment-of-bone-metastasis
#7
Guojing Luo, Yuedong He, Qian Zhao, Xijie Yu
BACKGROUND: Bone metastasis is a common complication of certain types of cancer, and unfortunately, it is still incurable to date. Immune system is a major defence against tumor cells and bone metastasis. However, the immunodeficient mouse models are widely used in most researches of bone metastasis, thereby excluding the regulatory roles of the immune system in bone metastasis. OBJECTIVE: The aim was to provide a comprehensive overview on the cellular and molecular mechanisms by which immune cells interact with tumor cells and bone cells, as well as recent related patents...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28482792/poly-adp-ribosyl-polymerase-1-inhibitors-a-patent-review
#8
Mengda Cao, Xi Sun, Yanjun Zhou, Wen Huang, Ling Meng, Ji-Fu Wei
BACKGROUND: Poly (ADP-ribosyl) polymerase 1 (PARP1) is important in maintaining genomic stability, repairing DNA damage, and regulating transcriptional processes. Altered PARP1 activity is associated with a multitude of pathologies especially cancer. The broad application prospects of PARP1 inhibitors attract many well-known pharmaceutical companies, which promotes the development of PARP1 inhibitors. OBJECTIVE: Present review aims to introduce PARP1 inhibitors by their structures and try to point out future development direction of PARP1 inhibitors...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28443515/indication-of-bevacizumab-for-cerebral-radiation-necrosis
#9
Hongqing Zhuang, Xiangkun Yuan, Zhiyong Yuan, Ping Wang
BACKGROUND: The effect of bevacizumab (BVZ) for Cerebral Radiation Necrosis (CRN) was clear. However, the indications of BVZ had no reports. OBJECTIVE: The aim of the paper was to investigate the indications of BVZ for CRN. METHODS: Fourteen CRN patients (confirmed by imaging diagnosis) who underwent BVZ treatment between June 2011 and December 2014 were analyzed. BVZ was administered (5mg/kg body weight) once every three to four weeks for at least three cycles...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28440207/epithelial-mesenchymal-transition-in-cancer-progression-prev-entive-phytochemicals
#10
Soorya P Illam, Arunaksharan Narayanankutty, Shaji E Mathew, Remya Valsalakumari, Rosemol M Jacob, Achuthan C Raghavamenon
BACKGROUND: Epithelial-Mesenchymal Transition (EMT) is the conversion of epithelial cells into mesenchymal phenotype generally observed during embryogenesis and wound healing as well as in malignant transformation. Several signaling pathways and transcription factors associated with EMT have been explored. Dietary phytochemicals that are multi-targeted agents which interfere with these pathways, assume preventive potential against pathologic EMT. OBJECTIVE: The present review aims to provide a detailed description of the nature and characteristics of EMT in physiological and pathophysiological conditions and the scope of phytochemicals in its prevention...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28440206/role-of-foxm1-in-the-progression-and-epithelial-to-mesenchymal-transition-of-gastrointestinal-cancer
#11
Jing Zhang, Yangyang Niu, Chen Huang
Gastrointestinal (GI) cancer, characterized by its leading mortality, is one of the most common cancers worldwide. The underlying mechanisms contributing to epithelial to mesenchymal transition (EMT) and metastasis of GI cancer are poorly understood. It is well known that a great number of transcription factors including FoxM1, KLF4, STAT3 and so forth, are associated with the process of EMT and have also been strongly implicated in the proliferation, migration, and invasion of GI cancer cells. Forkhead box M1 (FoxM1), a transcription factor of the Forkhead family, is strongly positive in GI cancers and can be regarded as an oncogene in GI cancers...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28440205/in-vitro-collapsing-colon-cancer-cells-by-selectivity-of-disulfiram-loaded-charge-switchable-nanoparticles-against-cancer-stem-cells
#12
Marwa M Abu-Serie, Fatma H El-Rashidy
BACKGROUND: Different strategies against colon cancer are accompanied by treatment failure, because of drug toxicity toward normal cells and cancer stem cells (CSCs) resistance. However, previous patent evaluated liposome that encapsulated inhibitor of CSCs' aldehyde dehydrogenase (ALDH)1; disulfiram, for targeting breast CSCs. Liposome has disadvantages due to its hydrophobicity. OBJECTIVES: Designing hydrophilic nanoparticles has selectivity to release disulfiram in CC cells rather than in normal colonocytes based on variation in microenvironment between normal and cancer cells...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28284026/editorial-thematic-issue-modulation-of-proteostasis-and-proteolytic-pathways-as-an-anti-cancer-strategy
#13
EDITORIAL
David M Pereira
No abstract text is available yet for this article.
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28245776/activating-mutations-of-esr1-brca1-and-cyp19-aromatase-genes-confer-tumor-response-in-breast-cancers-treated-with-antiestrogens
#14
Zsuzsanna Suba
BACKGROUND: Four decades of erroneous breast cancer therapy with antiestrogens yielded the chaotic mixture of manifestations of artificial ER-inhibition and compensatory activating ER-mutations together with unreckonable tumor responses. OBJECTIVE: Due to the confusions between the anticancer and carcinogenic impacts of antiestrogens and synthetic estrogens, the old principle needs to be revised as concerns ER-signaling induced DNAdamage and breast cancer development...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28164756/integrin-targeted-peptide-and-peptidomimetic-drug-conjugates-for-the-treatment-of-tumors
#15
D Arosio, L Manzoni, C Corno, P Perego
BACKGROUND: Integrins are heterodimeric cell surface receptors that mediate cell-cell and cell-extracellular matrix adhesion. These molecules play a role in processes such as cell growth and proliferation, differentiation, migration, cell trafficking, besides contributing to angiogenesis and tumor development. Given their biological role, integrins have been proposed as amenable targets in medicinal chemistry. In particular, αvβ3, αvβ5, αvβ6 and α5β1, integrins involved in tumor angiogenesis and metastasis, have been the subject of studies aimed at the discovery of novel cancer therapeutics...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28137213/docking-and-qsar-studies-of-1-4-dihydropyridine-derivatives-as-anti-cancer-agent
#16
Shirin Mollazadeh, Jamal Shamsara, Maryam Iman, Farzin Hadizadeh
BACKGROUND: The multidrug resistance (MDR) of cancer cells has become a great barrier to the success of chemotherapy. OBJECTIVE: In this study, quantitative structure activity relationship (QSAR) modeling was applied to 46 1,4-dihydropyridine structures (DHPs), and some selected compounds were docked. METHODS: QSAR was used to generate models and predict the MDR inhibitory activity for a series of 1,4-dihydropyridines (DHP). The DHPs were built and optimized using the Sybyl program (x1...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28067173/marine-derived-anticancer-drugs-targeting-microtubule
#17
Oindrila De, Biswa P Chatterji
BACKGROUND: Microtubule dynamics plays a vital role in regulating crucial cellular functions and is one of the most attractive anticancer drug targets. Microtubule targeting agents (MTAs) such as the vinca alkaloids or taxanes, although are effective for cancer therapy, have adverse side effects. Another hindrance in their development is multiple drug resistance in tumor cells. These drawbacks have urged the need to develop novel MTAs from alternative sources, with better therapeutic efficacy...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/28056753/role-of-ncrnas-in-development-diagnosis-and-treatment-of-human-cancer
#18
Francisco E Nicolas
BACKGROUND: Since the first reports of microRNAs and the advent of new sequencing technologies, a whole new world of regulatory non-conding RNAs (ncRNAs) has revolutionized our knowledge of the RNA dimension. Thousands of functional non-coding transcripts have been identified and grouped into new classes of ncRNAs attending to their origin and function. Despite the fact that we have just started to study ncRNAs, it is now clear that these new regulatory actors play an important role in most of the regulated biological processes and in almost all species...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/27881057/recent-patents-on-heat-shock-proteins-targeting-antibodies
#19
REVIEW
Joao C Fernandes, Pedro Alves
BACKGROUND: Heat shock proteins (Hsp) are major chaperone molecules that have recently emerged as cancer therapeutic targets owing to their involvement in tumor cell proliferation, differentiation, invasion and metastasis. High levels of extracellular Hsp90 and Hsp70 have been closely associated with a wide range of human cancers. Accumulating evidence suggests that the pharmacological inhibition of these molecules can play a pivotal role in non-surgical cancer treatment. Efforts have been taken to develop monoclonal antibodies (mAbs) and antibody fragments targeting extracellular Hsp90 and Hsp70, alone or conjugated with standard anticancer agents, to control several types of cancer, such as breast, colon, prostate or melanoma...
2017: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/27881056/recent-patents-on-proteasome-inhibitors-of-natural-origin
#20
REVIEW
Daniela Correia da Silva, Paula B Andrade, Vera Ribeiro, Patricia Valentao, David M Pereira
BACKGROUND: The proteasome is the major proteolytic site on the eukaryotic cell, degrading most of its short-lived or misfolded polypeptides. The ubiquitin-proteasome pathway has been found to play a fundamental role in the development of several pathologies, from cancer to neurodegenerative diseases, or even retroviral infections. Nature remains a powerful source for the discovery of bioactive compounds. Recently, a number of molecules of natural origin, as well as natural product derivatives, have been described as proteasome inhibitors...
2017: Recent Patents on Anti-cancer Drug Discovery
journal
journal
41278
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"